N/A
N=664
Clinical Utility of Postoperative Hemoglobin Testing
Anaemia Postoperative
Bottom Line
View on ClinicalTrials.gov: NCT04170764 ↗Enrolled (actual)
664
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcome: Primary: Number of Subjects With POD1 Hemoglobin Less Than 10 g/dL — 97 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- TriHealth Inc.
- Primary completion
- May 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects With POD1 Hemoglobin Less Than 10 g/dL |
97 | — |
Summary
The purpose of this study is to evaluate how many patients have hemoglobin less than 10 g/dL at post-operative day 1
Eligibility Criteria
Inclusion Criteria
- Total vaginal hysterectomy with or without bilateral salpingectomy/oophorectomy (CPT 58260, 58262, 58263, 58270, 58290, 58291, 58292, 58294)
- At least one of the following vaginal native tissue prolapse repairs
- Apical repair with uterosacral ligament suspension (CPT 57283)
- Apical repair with sacrospinous ligament fixation (CPT 57282)
- Anterior repair (CPT 57240, 57260, 57284, 57285, 57250)
- Posterior repair (CPT 45560, 56800, 56810, 57200, 57210, 57250)
- Surgery by one of four fellowship trained urogynecologists at TriHealth
Exclusion Criteria
- Concomitant surgical procedure by a second surgeon
- Malignancy identified at the time of surgery or active malignancy
- Cases converted to open hysterectomy or prolapse repairs
- Prolapse repair completed robotically
- Prolapse repair completed with mesh
- Known coagulopathy
- Patient on long term preoperative anticoagulant medication (Arixtra, Coumadin, Eliquis, Heparin, Lovenox, Pradaxa, Savaysa, Xarelto)
Data sourced from ClinicalTrials.gov (NCT04170764). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.